CorMedix Stock (NASDAQ:CRMD)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$6.30

52W Range

$5.60 - $17.43

50D Avg

$8.27

200D Avg

$11.00

Market Cap

$508.98M

Avg Vol (3M)

$2.85M

Beta

1.42

Div Yield

-

CRMD Company Profile


CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

64

IPO Date

May 13, 2010

Website

CRMD Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25
Product$304.34M

Fiscal year ends in Dec 25 | Currency in USD

CRMD Financial Summary


Dec 25Dec 24Dec 23
Revenue$311.71M$43.47M-
Operating Income$150.14M$-22.36M$-48.96M
Net Income$163.06M$-17.93M$-46.34M
EBITDA$150.14M$-18.98M$-46.23M
Basic EPS$2.25$-0.30$-0.91
Diluted EPS$2.04$-0.30$-0.91

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Mar 05, 26 | 8:30 AM
Q3 25Nov 12, 25 | 8:30 AM
Q2 25Aug 08, 25 | 8:30 AM

Peer Comparison


TickerCompany
TNGXTango Therapeutics, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
NBTXNanobiotix S.A.
PVLAPalvella Therapeutics, Inc.
SEPNSepterna, Inc.
KURAKura Oncology, Inc.
ABUSArbutus Biopharma Corporation
BCAXBicara Therapeutics Inc. Common Stock
PROKProKidney Corp.
SVRASavara Inc.